Osteopontin in the Cerebrospinal Fluid of Patients with Severe Aneurysmal Subarachnoid Hemorrhage.
biomarker
cerebrospinal fluid
inflammation
osteopontin
subarachnoid hemorrhage
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
10 07 2019
10 07 2019
Historique:
received:
27
05
2019
revised:
01
07
2019
accepted:
08
07
2019
entrez:
13
7
2019
pubmed:
13
7
2019
medline:
13
7
2019
Statut:
epublish
Résumé
Aneurysmal subarachnoid hemorrhage (SAH) is associated with high morbidity and mortality. In SAH patients, plasma osteopontin (OPN) has been shown to independently predict poor outcome. The aim of the study is to investigate, in a selected population with severe SAH, OPN time course in cerebrospinal fluid (CSF) and plasma during the first week after aneurism rupture, and OPN prognostic value. We included 44 patients with the following criteria: (1) age 18 and 80 years, (2) diagnosis of SAH from cerebral aneurysm rupture, (3) insertion of external ventricular drain. Plasma and CSF were sampled at day 1, 4, and 8. OPN levels, in CSF and plasma, displayed a weak correlation on day 1 and were higher, in CSF, in all time points. Only in poor prognosis patients, OPN levels in CSF significantly increased at day 4 and day 8. Plasma OPN at day 1 and 4 was predictor of poor outcome. In conclusion, plasma and CSF OPN displays a weak correlation, on day 1. The higher levels of OPN found in the CSF compared to plasma, suggest OPN production within the CNS after SAH. Furthermore, plasma OPN, at day 1 and 4, seems to be an independent predictor of poor outcome.
Identifiants
pubmed: 31295895
pii: cells8070695
doi: 10.3390/cells8070695
pmc: PMC6678172
pii:
doi:
Substances chimiques
Biomarkers
0
Osteopontin
106441-73-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Cell Physiol. 2000 Jul;184(1):118-30
pubmed: 10825241
Science. 2001 Nov 23;294(5547):1731-5
pubmed: 11721059
Eur J Neurosci. 2005 Apr;21(7):1911-20
pubmed: 15869484
N Engl J Med. 2006 Jan 26;354(4):387-96
pubmed: 16436770
Neurol Res. 2006 Jun;28(4):399-414
pubmed: 16759443
J Neurosurg. 2008 Jul;109(1):38-43
pubmed: 18593272
Cell Immunol. 2008;254(1):56-62
pubmed: 18678363
Intensive Care Med. 2008 Dec;34(12):2176-84
pubmed: 18807011
Crit Care Med. 2010 Feb;38(2):612-8
pubmed: 19851092
Stroke. 2010 Aug;41(8):1783-90
pubmed: 20616319
J Neurol. 2011 Mar;258(3):486-93
pubmed: 20967551
Ann Neurol. 2010 Nov;68(5):650-60
pubmed: 21031580
Glia. 2011 Mar;59(3):413-23
pubmed: 21264948
Cell Biol Int. 2012;36(12):1233-8
pubmed: 22974008
J Neurochem. 2012 Nov;123 Suppl 2:12-21
pubmed: 23050638
J Neuroinflammation. 2012 Nov 23;9:255
pubmed: 23176037
Stroke. 2013 Nov;44(11):3189-94
pubmed: 24008574
J Neurol Sci. 2014 Jun 15;341(1-2):119-27
pubmed: 24811975
Expert Opin Ther Targets. 2014 Aug;18(8):883-95
pubmed: 24899149
Minerva Anestesiol. 2015 Feb;81(2):157-65
pubmed: 24994498
Atherosclerosis. 2014 Oct;236(2):327-37
pubmed: 25128758
Front Neurol. 2015 Feb 18;6:26
pubmed: 25741315
Eur J Clin Invest. 2015 Jun;45(6):579-86
pubmed: 25845543
Int J Mol Sci. 2016 Apr 02;17(4):497
pubmed: 27049383
J Neuroinflammation. 2016 Aug 30;13(1):217
pubmed: 27576738
J Exp Med. 1989 Jul 1;170(1):145-61
pubmed: 2787378
J Immunol Res. 2016;2016:7675437
pubmed: 28097158
Biomed Res Int. 2017;2017:1879437
pubmed: 28698867
Mediators Inflamm. 2017;2017:4049098
pubmed: 28769537
Clin Chim Acta. 2017 Dec;475:64-69
pubmed: 29037840
Mol Neurobiol. 2018 Aug;55(8):6841-6849
pubmed: 29353454
Cells. 2019 Feb 18;8(2):
pubmed: 30781721
World Neurosurg. 2019 Feb;122:e612-e618
pubmed: 30814021
Stroke. 1995 Aug;26(8):1393-8
pubmed: 7631343
J Biol Chem. 1993 May 5;268(13):9901-7
pubmed: 8486670